The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Shares of Swedish Orphan Biovitrum AB (STO:SOBI) fell 3% as the company's fourth-quarter earnings report revealed mixed results. While overall Q4 revenue met consensus expectations, sales of its key ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024. Fourth Quarter 2024 Total revenue increased ...

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...

The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...